Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Amplexa Genetics A/S
A/S
Active
CVR 29428441
Sverigesgade 24, 5000
Odense C
Engineering activities and related technical consultancy
·
NACE 7112
Est. 2006 · 20 years old
12 employees
Monitor
Share
Denmark
/
Companies
/
Engineering activities and related technical consultancy
/
Amplexa Genetics A/S
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Gross profit
DKK millions
25M
19M
12M
6M
0M
2021: 20M
20M
2021
2022: 5M (-75% vs 2021)
5M
-75%
2022
2023: 3M (-40% vs 2022)
3M
-40%
2023
2024: 3M (0% vs 2023)
3M
0%
2024
2025: 4M (+33% vs 2024)
4M
+33%
2025
EBITDA
DKK millions
17M
9M
2M
-5M
-13M
2021: 11M
11M
2021
2022: -2M (-118% vs 2021)
-2M
-118%
2022
2023: -3M (-50% vs 2022)
-3M
-50%
2023
2024: -7M (-133% vs 2023)
-7M
-133%
2024
2025: -1M (+86% vs 2024)
-1M
+86%
2025
Income statement
DKK thousands
Item
2025
2024
2023
2022
2021
Gross profit
4.009
3.399
3.225
5.495
20.278
Staff expenses
-5.368
-6.405
-6.639
-7.228
-9.031
EBITDA
-1.359
-7.483
-3.414
-1.733
11.247
Depreciation & amort.
-371
-480
-649
-818
-810
EBIT
-1.730
-7.963
-4.063
-2.551
10.437
Net financials
-134
-31
17
-474
-495
Profit before tax
-1.864
-7.994
-4.046
-3.025
9.943
Tax
-281
3.115
-915
-742
-2.386
Net profit
-1.583
-11.108
-3.131
-2.282
12.328
Balance sheet
DKK thousands
Item
2025
2024
2023
2022
2021
Total assets
2.892
3.647
14.976
12.284
18.363
Equity
-10.313
-8.730
2.378
-14.491
-12.208
Long-term debt
11.810
10.610
10.610
25.610
26.260
Short-term debt
1.396
1.767
1.987
1.165
4.311
Total debt
13.206
12.377
12.597
26.775
30.571
Financial ratios
5-year trend
EBITDA margin (of gross profit)
-33,9 %
This company
2021
2025
Equity ratio
-356,6 %
This company
38,2 %
Market median
This company
Market median
>999% below market
2021
2025
Return on equity
—
This company
18,4 %
Market median
This company
Market median
2021
2025
Net profit margin (of gross profit)
-39,5 %
This company
2021
2025
Asset turnover (of gross profit)
1,39×
This company
2021
2025
Debt / equity
—
This company
0,62×
Market median
This company
Market median
2021
2025
Annual reports & filings
Annual report 2025
Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
View
PDF
More on Amplexa Genetics A/S
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
